

## Original Article

# *Clostridium difficile* colonization among patients with clinically significant diarrhea and no identifiable cause of diarrhea

Erik R. Dubberke MD, MSPH<sup>1</sup>, Kimberly A. Reske MPH<sup>1</sup>, Tiffany Hink BS<sup>1</sup>, Jennie H. Kwon DO, MSCI<sup>1</sup>, Candice Cass AA<sup>1</sup>, Jahnvi Bongu MPH<sup>1</sup>, Carey-Ann D. Burnham PhD<sup>2</sup> and Jeffrey P. Henderson MD, PhD<sup>1</sup>

<sup>1</sup>Division of Infectious Diseases, Washington University School of Medicine, St. Louis, Missouri and <sup>2</sup>Department of Pathology and Immunology, Department of Molecular Microbiology, and Department of Pediatrics, Washington University School of Medicine, St. Louis, Missouri

### Abstract

**Objective:** To determine the prevalence of *Clostridium difficile* colonization among patients who meet the 2017 IDSA/SHEA *C. difficile* infection (CDI) Clinical Guideline Update criteria for the preferred patient population for *C. difficile* testing.

**Design:** Retrospective cohort.

**Setting:** Tertiary-care hospital in St. Louis, Missouri.

**Patients:** Patients whose diarrheal stool samples were submitted to the hospital's clinical microbiology laboratory for *C. difficile* testing (toxin EIA) from August 2014 to September 2016.

**Interventions:** Electronic and manual chart review were used to determine whether patients tested for *C. difficile* toxin had clinically significant diarrhea and/or any alternate cause for diarrhea. Toxigenic *C. difficile* culture was performed on all stool specimens from patients with clinically significant diarrhea and no known alternate cause for their diarrhea.

**Results:** A total of 8,931 patients with stool specimens submitted were evaluated: 570 stool specimens were EIA positive (+) and 8,361 stool specimens were EIA negative (-). Among the EIA + stool specimens, 107 (19% of total) were deemed eligible for culture. Among the EIA - stool specimens, 515 (6%) were eligible for culture. One EIA + stool specimen (1%) was toxigenic culture negative. Among the EIA - stool specimens that underwent culture, toxigenic *C. difficile* was isolated from 63 (12%).

**Conclusions:** Most patients tested for *C. difficile* do not have clinically significant diarrhea and/or potential alternate causes for diarrhea. The prevalence of toxigenic *C. difficile* colonization among EIA - patients who met the IDSA/SHEA CDI guideline criteria for preferred patient population for *C. difficile* testing was 12%.

(Received 18 June 2018; accepted 13 August 2018; electronically published September 18, 2018)

Diagnosis of *Clostridium difficile* infection (CDI) poses a unique challenge to clinicians because detection of *C. difficile* from a stool specimen alone does not distinguish between colonization and CDI.<sup>1</sup> The “gold standard” method for *C. difficile* toxin detection in stool specimens, the cell culture cytotoxicity neutralization assay, is slow; toxin enzyme immunoassays (EIAs) are faster but less sensitive. Nucleic acid amplification tests (NAATs) are both sensitive and fast; however, because NAATs have greater analytical sensitivity to detect *C. difficile*, NAATs may have poor positive predictive value (PPV) for CDI.<sup>2</sup>

There is growing consensus that CDI diagnosis must combine laboratory results with appropriate clinical criteria, including presence of clinically significant diarrhea (CSD) and absence of other causes of diarrhea or worsening of diarrhea beyond what might otherwise be expected.<sup>3–6</sup> To this end, the recently released 2017 Infectious Diseases Society of America (IDSA)/Society for Healthcare Epidemiology of America (SHEA) Clinical Practice

Guidelines for CDI update emphasizes that the “preferred” patient population for *C. difficile* testing is patients with unexplained new-onset CSD, defined as  $\geq 3$  unformed bowel movements within 24 hours. If testing cannot be limited to the preferred testing population, the use of a stool toxin test as part of a multistep diagnostic algorithm is the preferred method of testing, and NAAT should not be used alone.<sup>7,8</sup> If it is possible to limit testing to the preferred testing population, it is recommended a NAAT alone can be an acceptable testing method, but an acceptable alternative is the use of a stool toxin test as part of a multistep algorithm. Data are limited, however, on the prevalence of *C. difficile* colonization among the preferred testing population; this prevalence may affect the PPV of NAATs for CDI. Thus, the first step toward determining the PPV of NAATs for CDI is to address the knowledge gap surrounding the prevalence of *C. difficile* colonization among patients who meet the IDSA/SHEA guideline-preferred patient population for *C. difficile* testing.

To address this need, a retrospective cohort was assembled of patients with stool specimens tested with a toxin EIA during routine clinical care from patients with documented CSD and no identifiable alternate causes of diarrhea. These stool specimens were cultured for toxigenic *C. difficile*, and *C. difficile* isolates underwent polymerase chain reaction (PCR) ribotyping to

**Author for correspondence:** Erik Dubberke MD, MSPH, Washington University School of Medicine, 4523 Clayton Ave, Box 8051, St Louis, MO 63110. E-mail: edubberk@wustl.edu

**Cite this article:** Dubberke ER, et al. (2018). *Clostridium difficile* colonization among patients with clinically significant diarrhea and no identifiable cause of diarrhea. *Infection Control & Hospital Epidemiology* 2018, 39, 1330–1333. doi:10.1017/ice.2018.225

determine the prevalence of *C. difficile* colonization among patients who met the IDSA/SHEA CDI clinical guidelines for the preferred *C. difficile* testing population.

## Methods

An aliquot from each stool specimen submitted to the Barnes-Jewish Hospital (BJH, St. Louis, MO) clinical microbiology laboratory for *C. difficile* testing has been collected and stored at  $-80^{\circ}\text{C}$ , quantity pending, since August 2014 for quality improvement purposes. Patients with stool specimens submitted for *C. difficile* testing at BJH from August 2014 through September 2016 by toxin EIA (Alere TOX A/B II, Abbott, Lake Bluff, IL) were eligible for inclusion. If a patient had >1 eligible stool specimens during an admission, the first stool specimen collected was used. Per hospital policy, only stool specimens that conformed to the shape of the container were tested for *C. difficile*. In May 2015, a restriction was placed on repeat testing if the patient had had a negative toxin EIA in the previous 4 days. The Washington University Human Research Protection Office approved this study.

Patients who did not have CSD or who had a potential alternate cause of diarrhea at the time the stool specimen was submitted for *C. difficile* testing were excluded. The hospital's medical informatics database was queried to obtain toxin EIA results, microbiology results for detection of non-*C. difficile* enteric pathogens from stool specimens, *International Classification of Disease, Ninth Revision, Clinical Modification* (ICD-9-CM) and *International Classification of Disease, Tenth Revision, Clinical Modification* (ICD-10-CM) procedure and diagnosis codes, and medications administered. Electronic data were used to exclude patients if they had the following potential alternate causes of diarrhea: history of inflammatory bowel disease, irritable bowel syndrome, or colectomy in the previous 10 years; chemotherapy in the 14 days before stool specimen collection; hematopoietic cell transplant in the 180 days before stool specimen collection; alternate gastrointestinal pathogen isolated from the stool specimen up to 7 days before or after the stool specimen selected for this project was collected; tube feeds in the 48 hours before collection or presence of an ostomy, ileostomy, or ileal conduit; laxatives within 24 hours of specimen collection; previous history of CDI; or CDI antimicrobial treatment in the 10 days before and after specimen collection (eg, oral vancomycin, oral or IV metronidazole, or oral fidaxomicin) for EIA negative (EIA-) stools only. All patients with EIA+ stool specimens received CDI treatment. Patients with an EIA- stool specimens who received CDI antimicrobial treatment within 10 days were excluded to ensure that patients with EIA-/toxicogenic culture+ stool specimens did not have CDI, which is the primary concern in using NAATs to aid in the diagnosis of CDI. Manual chart review was performed for all patients whose stool specimens were not excluded during electronic screening to determine whether the patients had any exclusion criteria that did not appear in the electronic data and whether the patients had CSD. All patients with CSD and no alternate cause of diarrhea were included in the study. Patients with EIA+/toxicogenic culture+ stool specimens were considered to have CDI, and patients with EIA-/toxicogenic culture+ stool specimens were considered colonized and without CDI.<sup>2,9-12</sup>

Stool specimens were cultured for *C. difficile* according to previously published methods.<sup>13</sup> Briefly, a 1-g aliquot of the stool

specimen was heat shocked at  $80^{\circ}\text{C}$  for 10 minutes, inoculated into cycloserine-cefoxitin mannitol broth with taurocholate and lysozyme (Anaerobe Systems, Morgan Hill, CA), and incubated anaerobically at  $35^{\circ}\text{C}$ . When turbid, the broth was inoculated onto pre-reduced blood agar (BAP, Becton Dickinson, Franklin Lakes, NJ). *Clostridium difficile* colonies were identified using matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) mass spectrometry (MS) with the Vitek MS platform (bioMérieux, Durham, NC). *Clostridium difficile* isolates were evaluated for the presence of *tcdA*, *tcdB*, and binary toxin genes (*cdtA/cdtB*) by multiplex PCR<sup>14-16</sup> and underwent ribotyping. The ribotyping banding patterns were analyzed using DiversiLab Bacterial Barcodes software (bioMérieux). Strains were compared with the Cardiff-ECDC collection of *C. difficile* strains for name assignment. Strains without a match in the Cardiff-ECDC collection were assigned a Washington University (WU) strain number.

## Results

A total of 8,931 patients had stool specimens tested for *C. difficile* during the study period (Fig. 1). Of these, 570 (6%) were EIA positive (EIA+) and 8,361 (94%) were EIA negative (EIA-). The electronic screening process excluded 293 EIA+ stool specimens and 5,809 EIA- stool specimens with potential alternate causes of diarrhea, leaving 277 EIA+ and 2,552 EIA- stool specimens eligible for chart review. The chart review process found an additional 169 EIA+ stools and 2,037 EIA- stool specimens from patients whose alternate cause of diarrhea was identified or for whom study investigators were unable to find documentation of CSD.

The remaining 107 EIA+ stool specimens (19% of all EIA+ stool specimens) and 515 EIA- stool specimens (6% of all EIA- stool specimens) met inclusion and exclusion criteria and were cultured for *C. difficile*. Among the EIA+ stool specimens, toxigenic *C. difficile* was isolated from 93 stool specimens (87%); 13 stool specimens (12%) could not be cultured due to insufficient stool volume; and 1 stool specimen (1%) was toxigenic culture negative. Among the EIA- stool specimens, *C. difficile* was not isolated from 409 stool specimens (79%), nontoxigenic *C. difficile* was isolated from 43 stool specimens (8%), and toxigenic *C. difficile* was isolated from 63 stool specimens (12%). Binary toxin was identified in 41 EIA+/toxicogenic culture+ isolates (44%) and 9 EIA-/toxicogenic culture+ isolates (14%). The 3 most common strains isolated from EIA+ stool specimens were ribotype 027 ( $n=35$ , 38%), ribotype 106/174 ( $n=14$ , 15%), and ribotype 002 ( $n=10$ , 11%). The 3 most common toxigenic strains isolated from EIA- stool specimens were ribotype 014/020 ( $n=10$ , 16%), followed by ribotype 027 ( $n=8$ , 13%); ribotype 001 ( $n=6$ , 10%), and ribotype 106/174 ( $n=6$ , 10%). None of the patients with EIA-/toxicogenic culture+ stool specimens had a documented microbiologically or clinically confirmed diagnosis of CDI within 30 days of the negative EIA.

## Discussion

Using very strict criteria to ensure no potential alternate causes of diarrhea, only 622 stool specimens (7%) submitted for *C. difficile* testing were from patients with documented CSD and met the IDSA/SHEA criteria for the preferred *C. difficile* testing population.<sup>7,8</sup> Among the stool specimens that were EIA+, 19% met




Fig. 1. Results of screening and *C. difficile* toxigenic culture.

these criteria; among EIA – stool specimens, only 6% did. Not surprisingly, toxigenic *C. difficile* was isolated from 93 of 94 (99%) EIA + stool specimens with sufficient stool for culture. This finding suggests that toxin EIA has excellent specificity for detecting patients with CDI among patients who meet the preferred *C. difficile* testing population definition. The most common strain isolated from EIA + stool specimens was ribotype 027, which was identified at a proportion similar to that seen in 2010 at BJH.<sup>14</sup> The 027 strain accounted for 35 of 41 strains (85%) isolated from EIA + stool specimens with binary toxin. Toxigenic *C. difficile* was isolated from 63 (12%) of patients with EIA – stool specimens. Compared with EIA + /toxigenic culture + stool specimens, *C. difficile* isolated from EIA – /toxigenic culture + stool specimens were less likely to have binary toxin. The strain distribution of toxigenic isolates from EIA – stool specimens was different than that from EIA + stool specimens. Ribotype 014/020 was the most common strain (16%), and ribotype 027 was the second most common strain (13%).

Most importantly, although all patients included in this study met the IDSA/SHEA criteria for the preferred *C. difficile* testing population, the recovery of toxigenic *C. difficile* from these EIA – stool specimens likely represented colonization and not CDI. Patients were excluded if they received empiric treatment for CDI (or were on metronidazole for other reasons), and no EIA – /toxigenic culture + patients were diagnosed with CDI within 30 days of when the stool specimen selected for this study was collected. The sensitivity of NAAT for detecting *C. difficile* from diarrheal stool specimens submitted for *C. difficile* testing compared to toxigenic culture in general has been found to be ~90% to 100%.<sup>17</sup> Toxigenic *C. difficile* was isolated from 156 stool specimens, 63 of which were EIA –. Excluding the EIA + stool specimens without sufficient stool for culture and assuming that

all NAATs would be positive from all EIA + /toxigenic culture + stool specimens, presumptively the PPV of NAAT for CDI from this population would be 60%–64%, similar to the PPV of NAATs for CDI seen when clinical presentation is taken into account.<sup>7,8,17</sup> Even if it were assumed that toxigenic *C. difficile* would have been recovered from the 13 EIA + stool specimens with insufficient stool for culture, the presumptive PPV of NAAT for CDI would be 63%–66%.

This study had several limitations. All stool specimens were initially submitted for *C. difficile* testing by clinicians and thus may have been subject to selection bias. As a retrospective study, it is possible that alternate, identifiable explanations for diarrhea could have been missed. Based on the number of patients excluded, we think that is unlikely. Notably, our definition for an alternate explanation for diarrhea was very broad because we felt it was more important to exclude a patient who did not necessarily have an alternate explanation for diarrhea than risk misclassifying a patient in the other direction. Although our exclusion criteria were very restrictive, they highlight the challenge of restricting *C. difficile* testing to patients who meet the preferred testing population. We were also unable to determine how many patients were excluded based on the lack of CSD alone; many patients had >1 reason for exclusion or were excluded using electronic data, from which CSD could not be determined. Another limitation of the definition is that patients can simultaneously have CDI and an alternate explanation for diarrhea. Also, we did not conduct NAATs, so the PPV of an NAAT among patients who met the IDSA/SHEA guideline–preferred *C. difficile* testing population criteria cannot be established and is based on conjecture. However, the sensitivity of the NAAT for detection of *C. difficile* from diarrheal stool specimens submitted for *C. difficile* testing compared to toxigenic culture is well established, and this

study was not large enough to definitively establish the PPV of NAAT among patients who meet the IDSA/SHEA guideline-preferred *C. difficile* testing population criteria.

In conclusion, the IDSA/SHEA CDI clinical guideline update recommendations for *C. difficile* testing are stratified based on whether testing can be restricted to patients with unexplained and new-onset CSD. The NAAT is recommended as a stand-alone test if testing can be restricted to this population. The purpose of this stratification is because NAATs can detect *C. difficile* colonization among patients with diarrhea for other reasons. However, we found that 12% of patients who met strict criteria for new-onset CSD and no identifiable alternate cause of diarrhea were colonized with *C. difficile*. Additional research is needed to determine the optimal role for NAAT testing when there is clinical concern for CDI and/or if other markers can differentiate between *C. difficile* colonization and CDI.

#### Acknowledgments.

**Financial support.** This work was supported by the Centers for Disease Control and Prevention's investments to combat antibiotic resistance under award number 200-2016-91939. Dr Kwon reports that the research reported in this publication was supported by the Washington University Institute of Clinical and Translational Sciences (grant no. UL1TR000448) and a subaward (grant no. KL2TR000450) from the National Center for Advancing Translational Sciences (NCATS) of the National Institutes of Health (NIH). The content is solely the responsibility of the authors and does not necessarily represent the official view of the NIH.

**Conflicts of interest.** Outside the submitted work, E.R.D. reports grants from Rebiotix; grants and personal fees from Pfizer and Merck; and personal fees from Valneva, Rebiotix, Achaogen, Biofire, Abbott, and Synthetic Biologics. Outside the submitted work, C.D.B. reports grants from bioMérieux, Cepheid, and Luminex; grants and personal fees from Accelerate Diagnostics; and personal fees from BioRad and the *Journal of Clinical Microbiology*. All other authors report no conflicts of interest.

#### References

- Burnham CA, Carroll KC. Diagnosis of *Clostridium difficile* infection: an ongoing conundrum for clinicians and for clinical laboratories. *Clin Microbiol Rev* 2013;26:604–630.
- Polage CR, Gyorke CE, Kennedy MA, et al. Overdiagnosis of *Clostridium difficile* Infection in the molecular test era. *JAMA Intern Med* 2015;175:1792–1801.
- Dubberke ER, Burnham CD. Diagnosis of *Clostridium difficile* infection: treat the patient, not the test. *JAMA Intern Med* 2015;175:1801–1802.
- Quan KA, Yim J, Merrill D, et al. Reductions in *Clostridium difficile* infection (CDI) rates using real-time automated clinical criteria verification to enforce appropriate testing. *Infect Control Hosp Epidemiol* 2018;39:625–627.
- Madden GR, German Mesner I, Cox HL, et al. Reduced *Clostridium difficile* tests and laboratory-identified events with a computerized clinical decision support tool and financial incentive. *Infect Control Hosp Epidemiol* 2018;39:737–740.
- Casari E, De Luca C, Calabro M, Scuderi C, Daleno C, Ferrario A. Reducing rates of *Clostridium difficile* infection by switching to a stand-alone NAAT with clear sampling criteria. *Antimicrob Resist Infect Control* 2018;7:40.
- McDonald LC, Gerding DN, Johnson S, et al. Clinical practice guidelines for *Clostridium difficile* infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). *Clin Infect Dis* 2018;66:987–994.
- McDonald LC, Gerding DN, Johnson S, et al. Clinical practice guidelines for *Clostridium difficile* infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). *Clin Infect Dis* 2018;66:e1–e48.
- Dubberke ER, Han Z, Bobo L, et al. Impact of clinical symptoms on interpretation of diagnostic assays for *Clostridium difficile* infections. *J Clin Microbiol* 2011;49:2887–2893.
- Kaltsas A, Simon M, Unruh LH, et al. Clinical and laboratory characteristics of *Clostridium difficile* infection in patients with discordant diagnostic test results. *J Clin Microbiol* 2012;50:1303–1307.
- Longtin Y, Trottier S, Brochu G, et al. Impact of the type of diagnostic assay on *Clostridium difficile* infection and complication rates in a mandatory reporting program. *Clin Infect Dis* 2013;56:67–73.
- Planche TD, Davies KA, Coen PG, et al. Differences in outcome according to *Clostridium difficile* testing method: a prospective multicentre diagnostic validation study of *C. difficile* infection. *Lancet Infect Dis* 2013;13:936–945.
- Hink T, Burnham CA, Dubberke ER. A systematic evaluation of methods to optimize culture-based recovery of *Clostridium difficile* from stool specimens. *Anaerobe* 2013;19:39–43.
- Alasmari F, Seiler SM, Hink T, Burnham CA, Dubberke ER. Prevalence and risk factors for asymptomatic *Clostridium difficile* carriage. *Clin Infect Dis* 2014;59:216–222.
- Dubberke ER, Reske KA, Seiler S, Hink T, Kwon JH, Burnham CA. Risk factors for acquisition and loss of *Clostridium difficile* colonization in hospitalized patients. *Antimicrob Agents Chemother* 2015;59:4533–4543.
- Westblade LF, Chamberland RR, MacCannell D, et al. Development and evaluation of a novel, semiautomated *Clostridium difficile* typing platform. *J Clin Microbiol* 2013;51:621–624.
- Crobach MJT, Baktash A, Duzenko N, Kuijper EJ. Diagnostic guidance for *C. difficile* infections. *Adv Exper Med Biol* 2018;1050:27–44.